Omron Healthcare Targets 3 Mn BP Monitors Annually by 2028, Eyes Chennai as Global Manufacturing Hub

The company plans to initially allocate the facility's entire output to the domestic market before developing Chennai as a manufacturing base for international markets.

Japan-based Omron Healthcare has started full-scale production at its first manufacturing facility in India near Chennai, targeting an annual production capacity of 3 million blood pressure (BP) monitors by 2028. The company plans to initially allocate the facility's entire output to the domestic market before developing Chennai as a manufacturing base for international markets.

Ayumu Okada, President and CEO of Omron Healthcare, said India remains an important growth market for the company, with significant opportunities to expand home blood pressure monitoring.

“During the initial phase, 100% of the factory’s production output will be allocated to the Indian domestic market,” Okada said, adding that the immediate priority is to supply products suited to Indian consumers and encourage wider adoption of home blood pressure monitoring.

The company is looking to tap India's largely underpenetrated home monitoring market. Despite the country's substantial hypertension burden, fewer than 5% of Indian households regularly use a home blood pressure monitor, according to Okada.

According to company estimates, Omron Healthcare held approximately 40% of India's home blood pressure monitor market in 2025. India accounted for around 3% of its global sales in FY2025, which ended in March 2026.

The approximately 24,000-square-metre Chennai facility commenced full-scale production in October. It currently operates five production lines manufacturing five blood pressure monitor models for the Indian market. The company has not disclosed the investment made in the facility or its expected first-year production volumes.

Over the medium to long term, Omron Healthcare aims to develop Chennai into a manufacturing base supplying healthcare devices to international markets, strengthening the flexibility and resilience of its global manufacturing network.

The company is also working to increase domestic sourcing of components. The facility handles processes from assembly to finished blood pressure monitors in India, using production technologies and quality-control expertise developed at its facilities in Japan and Vietnam.

“We are continuing to identify and develop relationships with local suppliers to increase the proportion of components sourced domestically, supporting the government’s Make in India initiative,” Okada said.

While local manufacturing is expected to improve logistics and domestic supply, the company has not committed to specific retail price reductions. It plans to focus on reliable, high-quality products suited to the Indian market, including affordability.

Omron Healthcare also plans to expand access to home blood pressure monitoring through increased domestic production, awareness initiatives and collaborations with healthcare professionals.

Stay tuned for more such updates on Digital Health News